Prucalopride: a new drug for the treatment of chronic constipation

References

• Lembo A, Camilleri M. Chronic constipation. N. Engl. J. Med.349(14), 1360–1368 (2003).
   PubMed Web of Science ®Google Scholar
• Pare P, Ferrazzi S, Thompson Wet al. An epidemiological survey of constipation in Canada, definitions, rates, demographics and predictors of health care seeking. Am. J. Gastroenterol.96, 3130–3137 (2001).
   PubMed Web of Science ®Google Scholar
• Longstreth G, Thompson W, Chey W, Houghton L, Mearin F, Spiller R. Functional bowel disorders. Gastroenterology130(5), 1480–1491 (2006).
   PubMed Web of Science ®Google Scholar
• Bracco A, Kahler K. Burden of chronic constipation must include estimates of work productivity and activity impairment in addition to traditional healthcare utilization. Am. J. Gastroenterol.99(Suppl. 10), S233 (2004).
   PubMed Web of Science ®Google Scholar
• Irvine EJ, Ferrazzi S, Pare P, Thompson WG, Rance L. Health-related quality of life in functional GI disorders, focus on constipation and resource utilization. Am. J. Gastroenterol.97(8), 1986–1993 (2002).
   PubMed Web of Science ®Google Scholar
• American College of Gastroenterology Chronic Constipation Task Force. An evidence-based approach to the management of chronic constipation in North America. Am. J. Gastroenterol.100, S1–S4 (2005).
   PubMedGoogle Scholar
• Tack J, Müller-Lissner S. Treatment of chronic constipation, current pharmacologic approaches and future directions. Clin. Gastroenterol. Hepatol.7(5), 502–508 (2008).
   PubMedGoogle Scholar
• Talley NJ. Functional gastrointestinal disorders as a public health problem. Neurogastroenterol. Motil.20(Suppl. 1), 121–129 (2008).
   PubMed Web of Science ®Google Scholar
• Gardner VY, Beckwith JV, Heyneman CA. Cisapride for the treatment of chronic idiopathic constipation. Ann. Pharmacother.29(11), 1161–1163 (1995).
   PubMedGoogle Scholar
• Tack J, Müller-Lissner S, Bytzer P et al. A randomised controlled trial assessing the efficacy and safety of repeated tegaserod therapy in women with irritable bowel syndrome with constipation. Gut54(12), 1707–1713 (2005).
   PubMed Web of Science ®Google Scholar
• Kamm MA, Müller-Lissner S, Talley NJ et al. Tegaserod for the treatment of chronic constipation, a randomized, double-blind, placebo-controlled multinational study. Am. J. Gastroenterol.100(2), 362–372 (2005).
   PubMed Web of Science ®Google Scholar
• Liu Z, Sakakibara R, Odaka T et al. Mosapride citrate, a novel 5-HT4 agonist and partial 5-HT3 antagonist, ameliorates constipation in Parkinsonian patients. Mov. Disord.20(6), 680–686 (2005).
   PubMed Web of Science ®Google Scholar
• Tack J, Middleton SJ, Horne MC et al. Pilot study of the efficacy of renzapride on gastrointestinal motility and symptoms in patients with constipation-predominant irritable bowel syndrome. Aliment Pharmacol. Ther.23(11), 1655–1665 (2006).
   PubMed Web of Science ®Google Scholar
• Scarpellini E, Tack J. Renzapride, a new drug for the treatment of constipation in the irritable bowel syndrome. Expert Opin. Investig. Drugs (11), 1663–1670 (2008).
   PubMedGoogle Scholar
• De Maeyer JH, Lefebvre RA, Schuurkes JA. 5-HT4 receptor agonists, similar but not the same. Neurogastroenterol. Motil.20(2), 99–112 (2008).
   PubMed Web of Science ®Google Scholar
• Dumuis A, Sebben M, Bockaert J. The gastrointestinal prokinetic benzamide derivatives are agonists at the non-classical 5-HT receptor (5-HT4) positively coupled to adenylate cyclase in neurons. Naunyn Schmiedebergs Arch. Pharmacol.340, 403–410 (1989).
   PubMed Web of Science ®Google Scholar
• Craig DA, Clarke DE. Peristalsis evoked by 5-HT and renzapride, evidence for putative 5-HT4 receptor activation. Br. J. Pharmacol.102, 563–564 (1991).
   PubMed Web of Science ®Google Scholar
• Briejer MR, Bosmans JP, Van Daele P et al. The in vitro pharmacological profile of prucalopride, a novel enterokinetic compound. Eur. J. Pharmacol.423(1), 71–83 (2001).
   PubMed Web of Science ®Google Scholar
• LePard KJ, Ren J, Galligan JJ. Presynaptic modulation of cholinergic and non-cholinergic fast synaptic transmission in the myenteric plexus of guinea-pig ileum. Neurogastroenterol. Motil.16(3), 355–364 (2004).
   PubMed Web of Science ®Google Scholar
• Prins NH, Van Haselen JF, Lefebvre RA, Briejer MR, Akkermans LM, Schuurkes JA. Pharmacological characterization of 5-HT4 receptors mediating relaxation of canine isolated rectum circular smooth muscle. Br. J. Pharmacol.127(6), 1431–1437 (1999).
   PubMed Web of Science ®Google Scholar
• Prins NH, Shankley NP, Welsh NJ et al. An improved in vitro bioassay for the study of 5-HT (4) receptors in the human isolated large intestinal circular muscle. Br. J. Pharmacol.129(8), 1601–1608 (2000).
   PubMed Web of Science ®Google Scholar
• Leclere PG, Prins NH, Schuurkes JA, Lefebvre RA. 5-HT4 receptors located on cholinergic nerves in human colon circular muscle. Neurogastroenterol. Motil.17(3), 366–375 (2005).
   PubMed Web of Science ®Google Scholar
• Prins NH, Akkermans LM, Lefebvre RA, Schuurkes JA. 5-HT4 receptors on cholinergic nerves involved in contractility of canine and human large intestine longitudinal muscle. Br. J. Pharmacol.131(5), 927–932 (2000).
   PubMed Web of Science ®Google Scholar
• Cellek S, John AK, Thangiah R et al. 5-HT4 receptor agonists enhance both cholinergic and nitrergic activities in human isolated colon circular muscle. Neurogastroenterol. Motil.18(9), 853–861 (2006).
   PubMed Web of Science ®Google Scholar
• Prins NH, van Der Grijn A, Lefebvre RA, Akkermans LM, Schuurkes JA. 5-HT4 receptors mediating enhancement of contractility in canine stomach; an in vitro and in vivo study. Br. J. Pharmacol.132(8), 1941–1947 (2001).
   PubMed Web of Science ®Google Scholar
• De Maeyer JH, Prins NH, Schuurkes JA, Lefebvre RA. Differential effects of 5-hydroxytryptamine4 receptor agonists at gastric versus cardiac receptors, an operational framework to explain and quantify organ-specific behavior. J. Pharmacol. Exp. Ther.317(3), 955–964 (2006).
   PubMedGoogle Scholar
• Leclere PG, Lefebvre RA. Presynaptic modulation of cholinergic neurotransmission in the human proximal stomach. Br. J. Pharmacol.135(1), 135–142 (2002).
   PubMed Web of Science ®Google Scholar
• Qi HB, Luo JY, Liu X. Effect of enterokinetic prucalopride on intestinal motility in fast rats. World J. Gastroenterol.9(9), 2065–2067 (2003).
   PubMed Web of Science ®Google Scholar
• De Winter BY, Boeckxstaens GE, De Man JG et al. Effect of different prokinetic agents and a novel enterokinetic agent on postoperative ileus in rats. Gut45(5), 713–718 (1999).
   PubMed Web of Science ®Google Scholar
• Briejer MR, Prins NH, Schuurkes JA. Effects of the enterokinetic prucalopride (R093877) on colonic motility in fasted dogs. Neurogastroenterol. Motil13(5), 465–472 (2001).
   PubMed Web of Science ®Google Scholar
• Emmanuel AV, Kamm MA, Roy AJ, Antonelli K. Effect of a novel prokinetic drug, R093877, on gastrointestinal transit in healthy volunteers. Gut42(4), 511–516 (1998).
   PubMed Web of Science ®Google Scholar
• Bouras EP, Camilleri M, Burton DD, McKinzie S. Selective stimulation of colonic transit by the benzofuran 5HT4 agonist, prucalopride, in healthy humans. Gut44(5), 682–686 (1999).
   PubMed Web of Science ®Google Scholar
• Poen AC, Felt-Bersma RJ, Van Dongen PA, Meuwissen SG. Effect of prucalopride, a new enterokinetic agent, on gastrointestinal transit and anorectal function in healthy volunteers. Aliment Pharmacol. Ther.13(11), 1493–1497 (1999).
   PubMed Web of Science ®Google Scholar
• De Schryver AM, Andriesse GI, Samsom M, Smout AJ, Gooszen HG, Akkermans LM. The effects of the specific 5HT4 receptor agonist, prucalopride, on colonic motility in healthy volunteers. Aliment Pharmacol. Ther.16(3), 603–612 (2002).
   PubMed Web of Science ®Google Scholar
• Bouras EP, Camilleri M, Burton DD, Thomforde G, McKinzie S, Zinsmeister AR. Prucalopride accelerates gastrointestinal and colonic transit in patients with constipation without a rectal evacuation disorder. Gastroenterology120(2), 354–360 (2001).
   PubMed Web of Science ®Google Scholar
• Sloots CE, Poen AC, Kerstens R et al. Effects of prucalopride on colonic transit, anorectal function and bowel habits in patients with chronic constipation. Aliment Pharmacol. Ther.16(4), 759–767 (2002).
   PubMed Web of Science ®Google Scholar
• Potet F, Bouyssou T, Escande D, Baró I. Gastrointestinal prokinetic drugs have different affinity for the human cardiac human ether-à-gogo K+ channel. J. Pharmacol. Exp. Ther.299(3), 1007–1012 (2001).
   PubMed Web of Science ®Google Scholar
• Chapman H, Pasternack M. The action of the novel gastrointestinal prokinetic prucalopride on the HERG K+ channel and the common T897 polymorph. Eur. J. Pharmacol.554(2–3), 98–105 (2007).
   PubMed Web of Science ®Google Scholar
• Mohammad S, Zhou Z, Gong Q, January CT. Blockage of the HERG human cardiac K+ channel by the gastrointestinal prokinetic agent cisapride. Am. J. Physiol.273(5 Pt 2), H2534–H2538 (1997).
   PubMed Web of Science ®Google Scholar
• Rampe D, Roy ML, Dennis A, Brown AM. Mechanism for the proarrhythmic effects of cisapride (Propulsid), high affinity blockade of the human cardiac potassium channel HERG. FEBS Lett.417(1), 28–32 (1997).
   PubMed Web of Science ®Google Scholar
• Pau D, Workman AJ, Kane KA, Rankin AC. Electrophysiological effects of prucalopride, a novel enterokinetic agent, on isolated atrial myocytes from patients treated with β-adrenoceptor antagonists. J. Pharmacol. Exp. Ther.313(1), 146–153 (2005).
   PubMed Web of Science ®Google Scholar
• De Maeyer JH, Schuurkes JA, Lefebvre RA. Selective desensitization of the 5-HT4 receptor-mediated response in pig atrium but not in stomach. Br. J. Pharmacol.156(2), 362–376 (2009).
   PubMed Web of Science ®Google Scholar
• Boeckxstaens GE, Bartelsman JF, Lauwers L, Tytgat GN. Treatment of GI dysmotility in scleroderma with the new enterokinetic agent prucalopride. Am. J. Gastroenterol.97(1), 194–197 (2002).
   PubMedGoogle Scholar
• Boyce MJ, Carey W, Mannaert EJ, Mertens A, Ausma J. Cardiovascular safety of prucalopride (Resolor ®) in healthy subjects, results from a randomized, double-blind, placebo-controlled, cross-over trial. Gastroenterology134, A551 (2008).
   Google Scholar
• Coremans G, Kerstens R, De Pauw M, Stevens M. Prucalopride is effective in patients with severe chronic constipation in whom laxatives fail to provide adequate relief. Results of a double-blind, placebo-controlled clinical trial. Digestion67(1–2), 82–89 (2003).
   PubMed Web of Science ®Google Scholar
• Tack J, van Outryve M, Beyens G, Kerstens R, Vandeplassche L. Prucalopride (Resolor) in the treatment of severe chronic constipation in patients dissatisfied with laxatives. Gut58(3), 357–365 (2009).
   PubMed Web of Science ®Google Scholar
• Camilleri M, Kerstens R, Rykx A, Vandeplassche L. A placebo-controlled trial of prucalopride for severe chronic constipation. N. Engl. J. Med.358(22), 2344–2354 (2008).
   PubMed Web of Science ®Google Scholar
• Quigley EM, Vandeplassche L, Kerstens R, Ausma J. Clinical trial, the efficacy, impact on quality of life, and safety and tolerability of prucalopride in severe chronic constipation – a 12-week, randomized, double-blind, placebo-controlled study. Aliment Pharmacol. Ther.29(3), 315–328 (2009).
   PubMed Web of Science ®Google Scholar
• Frank L, Kleinman L, Farup C, Taylor L, Miner P Jr. Psychometric validation of a constipation symptom assessment questionnaire. Scand. J. Gastroenterol.34(9), 870–877 (1999).
   PubMed Web of Science ®Google Scholar
• Marquis P, De La Loge C, Dubois D, McDermott A, Chassany O. Development and validation of the Patient Assessment of Constipation Quality of Life questionnaire. Scand. J. Gastroenterol.40(5), 540–551 (2005).
   PubMed Web of Science ®Google Scholar
• Thompson WG, Longstreth GF, Drossman DA, Heaton KW, Irvine EJ, Müller-Lissner SA. Functional bowel disorders and functional abdominal pain. Gut45(Suppl. 2), II43–II47 (1999).
   PubMed Web of Science ®Google Scholar
• Camilleri M, Gryp RS, Kerstens R et al. Efficacy of prucalopride (Resolor (R)) in patients with chronic constipation, pooled data from three pivotal Phase III studies. Gastroenterology134, A548 (2008).
   Google Scholar
• Mueller-Lissner SA, Rykx A, Kerstens Ret al. Randomized double-blind placebo-controlled trial to evaluate efficacy and safety of prucalopride (Resolor (R)) in elderly patients with chronic constipation. Gastroenterology134, A157 (2008).
   Google Scholar
• Krogh K, Jensen MB, Gandrup P, Laurberg S, Nilsson J, Kerstens R, De Pauw M. Efficacy and tolerability of prucalopride in patients with constipation due to spinal cord injury. Scand. J. Gastroenterol.37, 431–436 (2002).
   PubMed Web of Science ®Google Scholar
• Gatandiuk S, Beyens G, Ausma Jet al. Evaluation of the efficacy safety and tolerability of prucalopride (Resolor (R)) given subcutaneously in patients undergoing elective partial colectomies. Gastroenterology134, A138 (2008).
   Web of Science ®Google Scholar
• Tack J, Ausma J, Kerstens R et al. Safety and tolerability of prucalopride (Resolor ®) in patients with chronic constipation, pooled data from three pivotal Phase III studies. Gastroenterology134, A530 (2008) (Abstract).
   Google Scholar
• Van Outryve MJ, Beyens G, Kerstens R, Vandeplassche L. Long-term follow-up study of oral prucalopride administerd to patients with chronic constipation. Gastroenterology134, A547 (2008).
   Web of Science ®Google Scholar